TIDMFARN

RNS Number : 4715V

Faron Pharmaceuticals Oy

04 December 2023

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Grant of options

Company announcement, December 4, 2023 at 9 am (EET) / 7 am (GMT)

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the Company's board has confirmed the grant of a total of 34,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019 (including its UK and US sub plans). The Options have been allocated under the Share Option Plan 2019 and are exercisable between9 November 2024 and 9 November 2028, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is EUR3,53 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 9 November 2023. The exercise price for Options allocated under the US sub plan is EUR3,35 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 30 days preceding the allocation date of 9 November 2023. The terms of the Share Option Plan 2019 are available on the Company's website at https://www.faron.com/investors/general-meetings/2020.

The granted 34,000 Options entitle the option holders to subscribe for a total of 34,000 new ordinary shares in the Company, if exercised in full, and represent 0,05% of the fully diluted ordinary share capital of the Company.

Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs"), scientific advisory board ("SAB") members and Company personnel:

Director Options granted

Christine Roth 30,000

Total directors 30,000

Total Company personnel 4,000

For more information please contact:

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com

+1 (617) 430-7576

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com .

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
       Details of the person discharging managerial responsibilities/person 
  1     closely associated 
----  -------------------------------------------------------------------------------------------- 
 a.    Name                        Christine Roth 
                                  ---------------------------------------------------------------- 
       Reason for notification 
  2 
      --------------------------  ---------------------------------------------------------------- 
 a.    Position/Status             Person discharging managerial responsibilities/person 
                                    closely associated 
      --------------------------  ---------------------------------------------------------------- 
 b.    Initial notification/       Initial notification 
        Amendment 
      --------------------------  ---------------------------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------------------- 
 a.    Name                        Faron Pharmaceuticals Oy 
      --------------------------  ---------------------------------------------------------------- 
 b.    LEI                         7437009H31TO1DC0EB42 
      --------------------------  ---------------------------------------------------------------- 
       Details of the transaction(s): section to be repeated for 
  4     (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  -------------------------------------------------------------------------------------------- 
 a.    Description of              Options over ordinary shares 
        the financial 
        instrument, type            ISIN: FI4000153309 
        of instrument 
 
        Identification 
        Code 
      --------------------------  ---------------------------------------------------------------- 
 b.    Nature of the               Grant of options made under the Faron Share 
        transaction                 Option Plan 2019 US sub plans exercisable at 
                                    EUR3.35 per ordinary share. 
      --------------------------  ---------------------------------------------------------------- 
 
 c.    Price(s) and                     Price(s)       Volume(s) 
        volume(s) 
                                       ------------- 
    Nil                                                 30,000 
   -------------------------------------------------  --------------- 
 
 d.    Aggregated information 
 
        - Aggregated 
        Volume                       30,000 
 
        - Price                      Nil 
      --------------------------  ---------------------------------------------------------------- 
 e.    Date of the transaction     1 December 2023 
      --------------------------  ---------------------------------------------------------------- 
 f.    Place of the                Turku 
        transaction 
      --------------------------  ----------------------------------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHNKDBPOBDDCBK

(END) Dow Jones Newswires

December 04, 2023 02:00 ET (07:00 GMT)

Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Faron Pharmaceuticals Oy Charts.
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Faron Pharmaceuticals Oy Charts.